|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anti-interleukin-12 antibody for active Crohn' s disease 显示文摘 | Mannon PJ Fuss IJ Mayer L Elson CO Sandbom WJ Present D | 2004 | N EnglJ Med2004，351，20： | 1 |
| 2 | Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study显示文摘 | Sands BE Tremaine WJ Sandbom WJ | 2001 | Inflammatory Bowel Disease2001，7，2： | 1 |
| 3 | A review of activity indices and effi- cacy end points for clinical trials of medi- cal therapy in adults with ulcerative colitis显示文摘 | D Haens G Sandbom WJ Feagan BG | 2007 | Gastroenterology2007，132，2： | 1 |
| 4 | Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation显示文摘 | Sandbom WJ Rufo PA | 2003 | Am J Gastroenterol2003，98，6： | 1 |
| 5 | 显示文摘 | Sandbom WJ Feagan BG Hanauer SB | 2001 | Gastroenterology2001，120，6： | 1 |
| 6 | Azathioprine or 6-mercaptopurine for inducing remission of Crohn,s disease显示文摘 | Sandbom W Sutherland L Pearson D | 2000 | Co-chrane Database Syst Rev2000，，00： | 1 |
| 7 | Randomised clinical trial : the safety and tolerability of Trichuris suis ova in patients with Cmhn' s disease 显示文摘 | Sandbom WJ Elliott DE Weinstock J | 2013 | Aliment Pharmacol & Ther2013，38，3： | 1 |
| 8 | A review of immune modifier therapy for in- flammatory bowel disease: azathioprine, 6-mercaptopurine, eyclosporine, and methotrexate 显示文摘 | Sandbom W J | 1996 | Am J Gastroenterol1996，91，3： | 1 |
| 9 | Inflammatory bowel disease: clinical aspects and established and evolving therapies 显示文摘 | Baumgart DC Sandbom WJ | 2007 | Lancet2007，369，9573： | 1 |
| 10 | A randomized trial of ustekinumab,a human interleukin-12/23 monoclonal antibody,in patients with moderate-to-severe Crohn's disease显示文摘 | Sandbom WJ Feagan BG Fedorak RN | 2008 | Gastroenterology2008，135，4： | 1 |
| 11 | Review article:biological activity markers in inflammatory bowel disease显示文摘 | Desai D Faubion WA Sandbom WJ | | 0，，03： | 1 |
| 12 | To- facitinib, an oral janus kinase inhibitor, in- active ulcerative colitis显示文摘 | Sandbom W J Ghosh S Panes J | 2012 | N Engl J Med2012，367，7： | 1 |
| 13 | Advances in the treatment of Crohn's disease显示文摘 | Egan LJ Sandbom WJ | 2004 | Gastroenterol2004，126，： | 1 |
| 14 | Ustekinumab induction and maintenance therapy in refractory Crohn's disease显示文摘 | Sandbom WJ Gasink C Gao LL | 2012 | N Engl J Med2012，367，16： | 1 |
| 15 | Human anti-tumor necrosis factor monoclonal antibody (adalimumab)in Crohn's disease显示文摘 | Hanauer S B Sandbom W J Rutgeerts P | 2006 | Gastroenterology2006，130，2： | 1 |
| 16 | Treatment of ulcerative colitis with oral mesalamine : advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention显示文摘 | Sandbom WJ | 2006 | Rev Gastroenterol Disord2006，6，2： | 1 |
| 17 | An engineered human antibody to TNF (CDP571) for active Crohn' s disease: a randomized doubleblind plaeeho-controlled wial显示文摘 | Sandbom WJ Feagan BG Hanauer SB | 2001 | Gastroenterology2001，120，6： | 1 |
| 18 | Crohns disease in Olmsted County, Minnesota, 1940 - 1993 : Incidence, prevalence, and survival 显示文摘 | Loftus E V Silverstein M D Sandbom W J | 1998 | Gastroenterology1998，114，6： | 1 |
| 19 | Ulcerative cotitis in Olmsted Country, Minnesota, 1940-1993 ; incidence, prevalence,and survival显示文摘 | Loftus Jr EV Silverstein MD Sandbom W J | 2000 | Gut2000，46，3： | 1 |
| 20 | Infliximab for in-duction and maintenance therapy for ulcerative colitis 显示文摘 | Rutgeerts P Sandbom WJ Feagan BG | 2005 | NEngl J Med2005，353，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员